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Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this
study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-
remitting MS (RRMS) was compared by matching RCT to observational data.
Methods
Data from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity
score matched to data from the Italian multicenter database i-MuST. This database included
3,150 patients diagnosed between 2010 and 2018 at 24 ItalianMS centers who started a disease-
modifying drug. The annualized relapse rate (ARR) over 2 years from treatment start and the
24-week confirmed disability progression were compared between patients treated with cla-
dribine and other approved drugs (interferon, glatiramer acetate, fingolimod, natalizumab, and
dimethyl fumarate), with comparisons with placebo as a reference. Treatment effects were
estimated by the inverse probability weighting negative binomial regression model for ARR and
Cox model for disability progression. The treatment effect has also been evaluated according to
baseline disease activity.
Results
All weighted baseline characteristics were well balanced between groups. All drugs tested had an
effect vs placebo close to that detected in the RCT. Patients treated with cladribine had a
significantly lower ARR compared with interferon (relapse ratio [RR] = 0.48; p < 0.001),
glatiramer acetate (RR = 0.49; p < 0.001), and dimethyl fumarate (RR = 0.6; p = 0.001); a
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natalizumab (RR = 2.13; p = 0.014), confirming results obtained by indirect treatment comparisons from RCTs (network meta-
analyses). The relative effect of cladribine tablets 10 mg (cumulative dose 3.5 mg/kg over 2 years) was higher in patients with
high disease activity vs all treatments except fingolimod and natalizumab. Effects on disability progression were largely
nonsignificant, probably due to lack of power for such analysis.
Conclusion
In patients with RRMS, cladribine tablets showed lower ARR compared with matched patients who started interferon,
glatiramer acetate, or dimethyl fumarate; was similar to fingolimod; and was higher than natalizumab. The beneficial effect of
cladribine tablets was generally amplified in the subgroup of patients with high disease activity.
Classification of evidence
This study provides Class III evidence that for patients with RRMS, cladribine-treated patients had lower ARR compared with
interferon, glatiramer acetate, or dimethyl fumarate; similar ARR compared with fingolimod; and higher ARR compared with
natalizumab.
Relapsing-remitting MS (RRMS) is characterized by periodic
exacerbations of disease symptoms followed by periods of
remission, in which symptoms are either partially or com-
pletely absent. Disease-modifying drugs (DMDs) are able to
decrease the frequency and duration of relapses and some-
times to slow the progression of the disease.1
Cladribine tablet is hypothesized as an immune reconstitution
therapy that targets specific subsets of the adaptive immune
system.2 As demonstrated in the CLARITY phase 3 ran-
domized controlled study, a short-course treatment (8–20 d/y)
with cladribine tablets provided a sustained treatment benefit
for patients with RRMS.3 In particular, the 2 tested doses of
cladribine (3.5 and 5.25 mg/kg [3.5 mg/kg is the approved
dose]) were superior to placebo in suppressing relapse activity
and increasing the probability of remaining relapse-free. In the
CLARITY extension, the clinical benefits of 2 years of treat-
ment with cladribine tablets were shown to be sustained,
without the need for retreatment.4
In this study, we conducted a propensity score (PS)-matched
analysis of observational data from the CLARITY trial data set
and the Italian multicenter database i-MuST, which includes
3,150 patients diagnosed between 2010 and 2018 at 24 Italian
MS centers who started a DMD.
We aim to fill in the gap in the current RRMS treatment
landscape, as no direct head-to-head comparisons of cladribine
with other common immunotherapies have yet been con-
ducted. In particular, we try to define the role of cladribine
tablets in the context of the other available therapies for MS by
an individual-level comparative efficacy analysis of cladribine
tablets vs other common immunotherapies, such as interferon
beta (IFN β-1a and β-1b), glatiramer acetate (GA), fingolimod
(FTY), natalizumab (NTZ), dimethyl fumarate (DMF), and
teriflunomide (TERI), as first-line therapies for RRMS in Italy.
Methods
Patients
This is an observational retrospective study merging 2 data sets.
Details on the study design of the CLARITY data set can be
found in the article reporting the clinical trial results,3 and details
about the i-MuST database collection can be found in previous
publications.5 This study takes advantage of the availability of
the placebo arm of the CLARITY study, thus providing a ref-
erence to which each treatment can be compared.
Briefly, in the CLARITY study 1,326 patients were randomly
assigned in a 1:1:1 ratio to receive 1 of 2 doses of cladribine
tablets (either 3.5 mg or 5.25 mg/kg of body weight) or pla-
cebo. Patients randomized to the 3.5 mg/kg cumulative dose
received a first treatment course at weeks 1 and 5 of the first
year and a second treatment course at weeks 1 and 5 of the
second year. Patients were eligible if they had received a di-
agnosis of RRMS (according to the McDonald criteria, 20016),
had lesions consistent with MS on MRI, had had at least 1
relapse within 12 months before study entry, and had a score of
≤5.5 on the Expanded Disability Status Scale (EDSS).
The i-MuST data set is a multicenter, retrospective database,
involving 24 Italian MS centers. The data set used for this
analysis included 3,006 patients with RRMS. From these,
Glossary
ARR = annualized relapse rate;DMD = disease-modifying drug;DMF = dimethyl fumarate; EDSS = ExpandedDisability Status
Scale; FS = functional system; FTY = fingolimod; GA = glatiramer acetate; HAD = high disease activity; HR = hazard ratio;
IFN = interferon; IPW = inverse probability weighting; NMA = network meta-analysis; NTZ = natalizumab; PS = propensity
score; RRMS = relapsing-remitting MS; SC = subcutaneous; TERI = teriflunomide.
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patients satisfying the same inclusion/exclusion criteria as
CLARITY were extracted. Inclusion criteria were age over 16
years, diagnosis of RRMS (2001 International Panel Di-
agnostic Criteria and the 2010 revision6,7), and initiating a
DMD between January 2010 and June 2017. There were no
exclusion criteria. The EDSS score8 was collected for all pa-
tients at therapy start; at therapy switch (if any); every 6–12
months, depending on the center; and at the last follow-up.
Only treatment-naive patients were selected in the CLARITY
data set because all the patients enrolled in i-MuST were at
their first therapy. As a consequence, the study population was
defined as all enrolled patients in CLARITY who did not
receive any prior DMD and all the patients enrolled in
i-MuST who satisfied the inclusion criteria of CLARITY.
The following variables were common to the 2 data sets and
were merged: age at treatment start, disease duration since
onset, baseline EDSS score, presence of gadolinium-enhancing
(active) lesions at baseline, sex, relapses in the previous year, first
therapy, and date of first therapy start. First relapse, time to first
relapse, time to a progression event confirmed at 3 months, and
time to a progression event confirmed at 6 months were also
extracted fromCLARITY and calculated in the i-MuST data set.
The study population was split into the following treatment
groups: placebo, cladribine 3.5 mg/kg, cladribine 5.25 mg/kg,
IFN β-1a (subcutaneous [SC]), IFN-1a (SC), IFN β-1b, GA,
FTY, NTZ, DMF, and TERI. For treatment comparisons, the
IFNs were merged in a single IFN group and the 2 cladribine
tablets arms in a single cladribine-treated group. Therefore,
unless differently specified, the term IFN indicates the 3 IFNs
pooled together, and the term cladribine tablets indicates the
2 cladribine arms pooled together.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Ligurian Region ethical com-
mittee (258REG2016). All the centers involved in the study asked
for written permission of the use of anonymized personal clinical
data for research purposes, and written informed consent was
obtained from all study patients included in this study. CLARITY
registration—ClinicalTrials.gov number NCT00213135.
Outcomes
The primary end point for the Class III comparative effec-
tiveness analysis was annualized relapse rate (ARR) over 2
years. The secondary end point was time to onset of 24-week
sustained disability progression over 2 years. Patients in
i-MuST were censored at their treatment switch or at year 2,
whichever happened first.
Definition of relapses in i-MuST followed clinical trial criteria:
change in the EDSS score, with an increase of ≥0.5 points on
the total score, or an increase of 1 point on 2 functional systems
(FSs) or 2 points on 1 FS, excluding changes involving bowel/
bladder or cerebral FS. In CLARITY, the definition of relapses
closest to those defined in i-MuST was identified to be that of
“qualifying relapses,” and this variable was used for the analysis.
The ARR for each treatment group was calculated as the total
number of relapses experienced in the group divided by the
total number of patient-years on study.
The time to onset of 24-week confirmed disability pro-
gression is defined as the time from baseline to the first
disability progression that is confirmed at the next visit ≥24
weeks after the initial disability progression. Disability pro-
gression was defined by 1 of the following: an EDSS score
increase of ≥1.5 points from a baseline EDSS score of 0 that
is sustained for ≥12 weeks and an EDSS score increase of
≥1.0 point from a baseline EDSS score of 1.0–5.5 (inclusive)
for ≥24 weeks.
The date of the initial EDSS assessment at which the mini-
mum increase in the EDSS score is met was the date of onset
of the progression. The progression was defined as confirmed
when this minimum EDSS change was present on the next
study visit occurring after 24 weeks or longer from the onset
of the progression. EDSS assessments ≤30 days after a
protocol-defined relapse were not used for confirmation of
disability progression. If a patient met the defined criteria of
confirmed progression and was also having a relapse, the
patient was required to meet the defined minimum criteria at
the subsequent visit.
Patients without a confirmed progression based on the above
rules were censored. The censor date was the date of last EDSS
assessment in the study. Patients who withdrew from the study
after the baseline visit but before the first clinical evaluation
scheduled visit were censored at baseline.
Statistical methods
Baseline was defined for the i-MuST database as the start of
therapy date and for the CLARITY database as the randomi-
zation date. Baseline disease and demographic characteristics
were summarized by group and overall before any adjustment,
using descriptive statistics, and were compared between treat-
ment groups using the standardized mean difference as calcu-
lated according toCohen d effect size. ACohen d effect size >0.1
denotes meaningful imbalance in the baseline covariates.9–14
Tomitigate the baseline differences between compared groups,
the inverse probability weighting (IPW) approach based on PS
was used. The weights correspond to the inverse of the con-
ditional PS of receiving the treatment. The PSwas calculated by
modeling on the baseline characteristics the probability of re-
ceiving each treatment vs another one by a logistic regression
model applied to each treatment group in the i-MuST study vs
the overall CLARITY study population (since the assignment
to cladribine tablets or placebo was randomized). The logistic
regression model had treatment group as the dependent vari-
able (placebo/cladribine tablets vs other drug) and the fol-
lowing baseline variables as independent covariates: age,
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disease duration since onset, baseline EDSS score, sex, and
relapses in the previous year.
We used stabilized trimmed weights (weights that exceeded a
specified threshold are each set to that threshold15) to mitigate
the impact of extremely higher or lower weights on the vari-
ability of the estimated treatment effect.15 The threshold was
based on the quantiles of the distribution of the weights (1st to
5th and 95th to 99th percentiles).15,16 For each treatment pair,
we choose to trim the weights at the percentile giving the
highest reduction of standardized Cohen d differences.
An IPW negative binomial regression model was used to
assess differences between treatments on relapse rate over 2
years. The relapse count was used as a dependent variable,
the treatment group as an independent variable, and the log
of follow-up duration as an offset variable.
The semiparametric IPW Cox regression model was used
to assess treatment effect differences on time to disability
progression. Cumulative probability to be progression-
free during follow-up was calculated and graphically
displayed by mean of Kaplan-Meier survival curves. The
estimates of treatment effect were expressed as hazard
ratios (HRs) and reported with 95% CIs and p values. Stata
(v.14; StataCorp., College Station, TX) was used for the
computation.
Subgroup analyses
A subgroup analysis assessed the relative treatment effect of
each drug vs cladribine tablets in subgroups of patients de-
fined according baseline disease activity. The definition of
patients with high disease activity (HDA) at baseline was the
one used in a previous article,4 as patients with ≥2 relapses
during the year before study entry, whether on DMD. The
definition including patients with previous relapses while on
treatment was not applied here because only naive patients
were included in the analyzed cohorts.
All the analyses run on the overall population were rerun on
subgroups of patients with and without HDA at baseline. The
significance of the difference in treatment effects between
subgroups was assesses by interaction tests. The results were
displayed by forest plots.
Sensitivity analyses
The following sensitivity analyses were run: (1) analyses with a
PS and IPW calculated including baseline MRI information,
run on a reduced sample; (2) analyses including patients
treated with cladribine tablets 3.5 mg/kg only; (3) analyses
adjusted by a 1:1 PS matching and a variable ratio ≤3:1 PS
matching; and (4) analysis contrasting cladribine tablets vs each
IFN separately.
Data availability




A total of 2,204 patients from i-MuST and 945 patients from
CLARITY were included in the final analysis. Supplementary
figure e-1 (links.lww.com/NXI/A298) presents the flowchart
for selecting patients from the i-MuST andCLARITY data sets.
In the i-MuST data set, a total of 1,168 patients were treated
with IFN, 402 with GA, 113 with FTY, 149 with NTZ, 295
with DMF, and 77 with TERI. In the CLARITY data set, 305
were in the placebo arm, 322 received the cladribine 3.5 mg/
kg dose, and 318 received the cladribine 5.25 mg/kg dose.
The unweighted characteristics of all patients included in the
analysis, according to the treatment group in the i-MuST da-
tabase and in CLARITY, are presented in table e-1 (links.lww.
com/NXI/A298). In CLARITY, patients were randomized
among treatment arms; therefore, data are presented here for
the overall CLARITY study, according to the IPW approach
used. The baseline characteristics detailed for each treatment
arm are reported in table e-2.
Patients included in i-MuSTwere generally younger (excluding
patients treated with GA, who were in the same age range, and
patients treated with TERI, who were older) than patients
included in CLARITY. EDSS levels were generally well bal-
anced (small standardized differences in range of 0.20–0.37)
between CLARITY patients and patients treated with FTY,
NTZ, and TERI, whereas patients treated with IFN, GA, and
DMF had lower EDSS baseline scores. Disease duration was
generally lower in i-MuST compared with CLARITY patients
with mild to moderate differences. Patients enrolled in i-MuST
(especially FTY, NTZ, and DMF) showed a higher frequency
of active lesions at baseline compared with trial data. Follow-up
duration was lower in i-MuST for patients treated with FTY,
DMF, and TERI. The mean time between visits with the EDSS
was 157 days with amedian of 109 days. Baseline characteristics
for each treatment and for CLARITY study after IPW are
presented in table 1. The 3 arms of CLARITY are shown
separately and compared with each treatment in tables e-3 to
e-8 (links.lww.com/NXI/A298).
The weighted characteristics were well balanced between each
treatment group from the i-MuST and CLARITY data sets. A
residual unbalance persisted for the EDSS in the IFN and GA
arms (with standardized difference in range of 0.25–0.34).
Comparative effectiveness analyses
Annualized relapse rate
The IPW-adjusted ARR for each treatment arm is reported in
table 2. Treatment with cladribine tablets was associated with
a statistically significant reduction in ARR of 52% vs IFN, 51%
vs GA, and 40% vs DMF. The reduction of ARR vs FTY was
not statistically significant (p = 0.24); NTZ was superior to
cladribine tablets, and the ARR ratio of cladribine vs NTZ was
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Table 1 Inverse probability-weighted demographic and clinical characteristics






difference IFN vs CLARITY
CLARITY
(n = 945) GA (n = 402)
Standardized mean
difference GA vs CLARITY
CLARITY
(n = 945) FTY (n = 113)
Standardized mean
difference FTY vs CLARITY
Age, y, mean (SD) 37.3 (10.1) 36.6 (10.7) 0.071 38.8 (10.2) 39.5 (11.8) 0.07 38.4 (10.3) 38.1 (11.6) 0.025



































1.32 (0.56) 1.33 (0.58) 0.013 1.33 (0.58) 1.32 (0.56) 0.024 1.35 (0.6) 1.36 (0.57) 0.01
Active lesions, n (%) 306 (32.4) 435/1,023
(42.5)
0.21 290 (30.7) 146/376
(38.7)
0.17 294 (31.1) 48/90 (53.3) 0.46
Panel B: NTZ, DMF, and TERI vs CLARITY study
CLARITY
















Age, y, mean (SD) 37.9 (10.4) 36.6 (10.9) 0.12 38.3 (10.3) 38.1 (10.2) 0.015 39.1 (10.4) 39.3 (11.8) 0.019
Females, n (%) 609 (64.4) 84 (56.4) 0.17 617 (65.3) 197 (66.8) 0.03 614 (65) 45 (58.4) 0.13



































ARR in previous year,
mean (SD)
1.36 (0.61) 1.42 (0.66) 0.089 1.32 (0.57) 1.29 (0.53) 0.068 1.33 (0.58) 1.32 (0.57) 0.017
Active lesions, n (%) 299 (31.7) 89/128 (69.5) 0.82 293 (31) 134/276
(48.6)
0.36 287 (30.4) 19/72 (26.4) 0.088
Abbreviations: ARR = annualized relapse rate; DMF = dimethyl fumarate; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GA = glatiramer acetate; HDA, high disease activity; IFN = interferon β; IQR = interquartile

































Table 2 ARR after IPW adjustment in all the analyzed treatment groups
IPW clinical variables IPW clinical + MRI variables
ARR (95% CI)
ARR ratio (95% CI)
ARR (95% CI)
ARR ratio (95% CI)
IFN vs placebo Cladribine vs IFN IFN vs placebo Cladribine vs IFN
Placebo 0.321 (0.275–0.367) 0.76 (0.64–0.91); p = 0.002 0.48 (0.41–0.57); p < 0.001 0.319 (0.273–0.365) 0.79 (0.66–0.95); p = 0.011 0.46 (0.38–0.55); p < 0.001
Cladribine 0.118 (0.101–0.134) 0.116 (0.099–0.132)
IFN 0.246 (0.222–0.269) 0.252 (0.226–0.279)
GA vs placebo Cladribine vs GA GA vs placebo Cladribine vs GA
Placebo 0.318 (0.254–0.382) 0.78 (0.57–1.08); p = 0.13 0.49 (0.36–0.68); p < 0.001 0.318 (0.254–0.383) 0.79 (0.57–1.09); p = 0.14 0.49 (0.36–0.68); p < 0.001
Cladribine 0.123 (0.099–0.147) 0.122 (0.098–0.147)
GA 0.249 (0.187–0.311) 0.250 (0.187–0.313)
FTY vs placebo Cladribine vs FTY FTY vs placebo Cladribine vs FTY
Placebo 0.320 (0.257–0.383) 0.54 (0.32–0.89); p = 0.016 0.74 (0.45–1.22); p = 0.24 0.321 (0.257–0.385) 0.47 (0.28–0.79); p = 0.005 0.84 (0.50–1.41); p = 0.51
Cladribine 0.127 (0.103–0.150) 0.127 (0.103–0.150)
FTY 0.171 (0.091–0.252) 0.151 (0.078–0.223)
NTZ vs placebo Cladribine vs NTZ NTZ vs placebo Cladribine vs NTZ
Placebo 0.326 (0.261–0.391) 0.18 (0.10–0.34); p < 0.001 2.13 (1.17–3.88); p = 0.014 0.329 (0.265–0.394) 0.17 (0.09–0.32); p < 0.001 2.28 (1.23–4.24); p = 0.009
Cladribine 0.128 (0.104–0.152) 0.128 (0.104–0.152)
NTZ 0.060 (0.026–0.094) 0.056 (0.023–0.089)
DMF vs placebo Cladribine vs DMF DMF vs placebo Cladribine vs DMF
Placebo 0.312 (0.246–0.377) 0.65 (0.44–0.97); p = 0.036 0.60 (0.41–0.89); p = 0.001 0.322 (0.256–0.387) 0.64 (0.43–0.94); p = 0.024 0.63 (0.43–0.93); p = 0.02
Cladribine 0.123 (0.099–0.147) 0.129 (0.104–0.154)
DMF 0.204 (0.135–0.272) 0.204 (0.136–0.273)
Abbreviations: ARR = annualized relapse rate; DMF = dimethyl fumarate; FTY = fingolimod; GA = glatiramer acetate; IFN = interferon β; IPW = inverse probability weighting; NTZ = natalizumab.

































2.13 (p = 0.014) (table 2). Cladribine tablets compared with
TERI was not analyzed because the TERI arm was too small
(n = 77) to drawmeaningful conclusions. The treatment effects
vs placebo were close to those observed in randomized con-
trolled trials and estimated in previous network meta-analyses
(table e-9 and figure e-2, links.lww.com/NXI/A298)17–19 with
largely overlapping CIs for all the drugs. In this study, NTZ
showed a reduction in the ARR vs placebo of 82% (with very
large CIs)—higher than that observed in the AFFIRM study
(ARR ratio vs placebo = 68%) and reestimated in the network
meta-analyses, but with overlapping CIs. Similar results were
obtained for the analysis including baseline MRI activity in the
PS calculation on the subgroup of patients with available MRI
information at baseline (table 2, second column). Forest plots
for these 2 analyses are presented in figure 1. Similar results
were obtained when considering the 2 different doses of cla-
dribine tablets separately (table e-10).
Our results of the effects of cladribine tablets vs other drugs on
ARR were compared with those reported by a previous net-
work meta-analysis (NMA) (figure e-3, links.lww.com/NXI/
A298).20 All the cladribine effects vs the other DMDs were
within the CIs of those estimated in the NMA.20
Disability progression
TheHRs for comparisons of disability progression are reported
in table 3 and displayed in figure e-4 (links.lww.com/NXI/
A298). A small proportion of patients had missing data on
follow-up EDSS. Excluded patients in each group were 40
(3.42%) for IFN; 23 (5.72%) for GA; 5 (4.4%) for FTY; 15
(10%) for NTZ; and 33 (11.2%) for DMF. A significant dif-
ference in favor of cladribine tablets on time to disability pro-
gression was observed only for GA (−36%; p = 0.045).
The survival curves for progression-free probability of each
treatment vs cladribine tablets 3.5 mg/kg are shown in figure
e-5 (links.lww.com/NXI/A298), whereas the HRs for com-
parisons of disability progression, considering the 2 different
doses of cladribine tablets separately, are reported in table e-11.
Figure 1 ARR ratio of cladribine vs other treatments
ARR = annualized relapse rate; DMF = dimethyl fumarate; FTY = fingolimod; GA = glatiramer acetate; IFN = interferon β; NTZ = natalizumab.
Table 3 Risk of 24-week disability progression of
cladribine vs other drugs
IPW clinical
variables
IPW clinical + MRI
variables
HR (95% CI) HR (95% CI)


















































Abbreviations: DMF = dimethyl fumarate; FTY = fingolimod; GA = glatiramer
acetate; HR = hazard ratio; IFN = interferon β; IPW = inverse probability
weighting; NTZ = natalizumab.
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Subgroup analyses
The effect of cladribine tablets vs other drugs was tested in
subgroups defined according to baseline disease activity.
The weighted baseline characteristics for each treatment
by subgroup (HDA vs non-HDA) are presented in tables
e-12 and e-13 (links.lww.com/NXI/A298). The same
characteristics are reported in tables e-14 to e-18 with the
3 arms of CLARITY presented separately. Results on ARR
are shown in figure 2. The effect of cladribine tablets was
generally amplified in the HDA subgroup and the same
was true for cladribine 3.5 mg alone (table e-19). The
subgroup analysis run on time to disability progression is
presented in tables e-20 and e-21. The same trend for a




Baseline characteristics of patients after 1:1 PS matching are
reported in table e-22 (links.lww.com/NXI/A298). A good
balance with standardized differences <0.10 for almost all
characteristics and treatments was observed. The ARR ratio
between cladribine tablets and single treatment arms after 1:1
PS matching (table e-23) confirmed in general the results
observed with the IPW approach.
PS matching 3:1
The characteristics of matched samples after up to 3:1 PS
matching are reported in table e-24 (links.lww.com/NXI/
A298). Here also a good balance was observed between the
Figure 2 Relapse rate ratio of cladribine vs each other treatment according to HDA subgroups
ARR = annualized relapse rate; CLAD = cladribine; DMD = disease-modifying drug; DMF = dimethyl fumarate; FTY = fingolimod; GA = glatiramer acetate; HDA,
high disease activity; IFN = interferon β; NTZ = natalizumab; RR = relapse ratio.
8 Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 6 | November 2020 Neurology.org/NN
compared groups. The ARR ratio between cladribine tablets
and single treatment arms after 3:1 PS matching (table e-25)
confirmed the results observed with the IPW approach.
Stratification of IFN arms
The IPW-weighted baseline characteristics of the 3 IFN arms
split are reported in table e-26 (links.lww.com/NXI/A298).
Good balance with standardized differences <0.10 was ob-
served for almost all characteristics across the 3 arms compared
with CLARITY. Theweighted ARR ratio (table e-27, links.lww.
com/NXI/A298) showed a higher effect of cladribine tablets in
IFN-1b and IFN-1a SC compared with IFN-1a IM.
Discussion
This study presents a novel approach, matching individual pa-
tient data from the CLARITY randomized controlled phase III
trial with those included in a large multicenter observational
study in newly diagnosed patients. The presence of the placebo
arm from CLARITY allowed us to compare, as a first step, the
effectiveness of each drug from the observational study vs pla-
cebo with the effect reported in randomized clinical trials. The
effect of each treatment vs placebo was close to that observed in
the clinical trials except for NTZ, where a larger effect in the
drug vs placebo was seen (ARR ratio 82% vs 68% reported in
the AFFIRM trial21), even if the large CIs of the estimate
obtained in this study limit the interpretation of such result.
The results from comparative effectiveness showed a superi-
ority of cladribine tablets vs IFN, GA, and DMF on the relapse
rate in the first 2 years. No significant differences were ob-
served with FTY, whereas NTZ was shown to be superior.
Similar results were observed in a previous observational study22
on comparative effectiveness of cladribine conducted in a cohort
of patients from the MSBase International Registry. A small
cohort of patients treated with cladribine vs FTY, NTZ, and IFN
showed a superiority of cladribine vs IFN and a superiority of
NTZ on cladribine on hazard of first relapse. On the same
outcome, no significant differences between cladribine and FTY
were detected. No comparisons vs GA or DMFwere performed.
A recent NMA20 compared the effects of various DMDs on
ARR and confirmed disability progression in active and highly
active RRMS, including 41 studies. Cladribine was ranked in
fourth position on a scale of efficacy for ARR reduction after
alemtuzumab, NTZ, and ocrelizumab. In the same NMA, a
significant reduction of ARR with cladribine, estimated around
40% vs GA and up to 48% vs IFN, was reported and was close
to that observed in our study. When compared with DMF, the
ARR reduction due to cladribine was not significant and lower
than that observed in our study (22%; 95% CI 43%–7%) in
NMA vs 36% in our study; our data are therefore consistent
with those reported in NMA). The ARR under cladribine was
comparable to FTY and higher than the ARR under NTZ, even
if the difference was not significant.
In the NMA,20 cladribine was statistically similar to the other
DMDs on confirmed disability progression. In our study, the
superiority of cladribine was detected only vs GA.
Cladribine is approved and indicated mainly for the treatment
of patients with highly active RRMS. Having individual pa-
tient data, we were able to perform a subgroup analysis, which
indicated a higher efficacy of cladribine vs other DMDs in
patients with HDA, with ARR reduction close to 70% vs IFN,
GA, and DMF in this specific subgroup of patients.
Study limitations
This study carries all the well-known limitations of non-
randomized comparisons, with the advantage of a placebo arm
giving a benchmark for comparisons.23 In addition, the sample
size for all the comparisons on disability progression was low,
giving estimates with large CIs. To mitigate the potential bias
due to the lack of randomization, we applied an IPW in the
main analysis as well as several sensitivity analyses with different
matching algorithms.
With our comparative results, based on a wide national data-
base (i-MuST) and the CLARITY data set, we simulated a
scenario representing the complexity of management of pa-
tients with MS, which confirms the effectiveness of cladribine
tablets in treating RRMS. Our approach let us overcome the
lack of direct head-to-head comparisons of cladribine tablets to
other common DMDs. We confirmed the superiority of cla-
dribine tablets in reducing relapse rate, during the first 2 years,
compared with its major competitors, such as IFN, GA, and
DMF; NTZ data were still superior as given in the results.
Finally, having individual patient data, we were able to show
the higher efficacy of cladribine in the subgroup of patients
with HDA.
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